Injury Lawyer Releases New Information Graphic on the Alleged Risks of Heartburn Drugs Like Prilosec
d'Oliveira & Associates has posted a new infographic about the proton pump inhibitor (PPI) Prilosec. The law firm works with some of the more experienced Prilosec lawyers, who handle these cases.
(PRWEB) October 02, 2013
Prilosec (omeprazole) is included in the proton pump inhibitor (PPI) class of drugs. These drugs are used to heart burn and related conditions like dyspepsia, peptic ulcer disease (PUD), and gastroesophageal reflux disease (GERD). In May 2010, the FDA warned that PPI drugs may be linked to an increased risk of fractures of the hip, spine, and wrist. In March 2011, this information was updated stating that “patients at highest risk for fractures received high doses of prescription PPIs” (i). People who have suffered fractures or broken bones due to taking Prilosec may want to talk to an attorney about their legal options.
A recent article from Forbes also investigated the cardiovascular safety of PPIs. The article reviewed a new study which found that medicine like Nexium and Prilosec may cause blood vessels to constrict and reduce blood flow. The study also revealed that PPIs led a 25% increase in ADMA (asymmetric dimethylarginine), which is an indicator of cardiovascular risk. John Cooke, the study’s author, stated that “there’s going to be more information coming out that will, in my opinion, raise concerns about the long-term effects of proton pump inhibitors and risk of heart damage” (ii).
The Prilosec infographic provides a timeline of the drug’s approval and subsequent FDA warnings. People who have been injured by this medicine may be able to recover medical expenses, lost income, pain and suffering, or other losses. d’Oliveira & Associates has been investigating allegations that PPIs may increase the risk of bone fractures. The law firm focuses its practice on injury lawsuits and disability claims. The firm works with some of the more experienced Prilosec lawyers and there are no legal fees unless a settlement or award is obtained. Contact the firm by calling 1-800-992-6878 or submit a contact form online.
(i) FDA Drug Safety Communication.
(ii) Forbes, July 2013.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/10/prweb11126341.htm